- Home
- CAPR vs ARMN Comparison
CAPR vs ARMN Comparison
Compare CAPR & ARMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- ARMN
- Stock Information
- Founded
- CAPR 2005
- ARMN 1992
- Country
- CAPR United States
- ARMN Canada
- Employees
- CAPR N/A
- ARMN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- ARMN
- Sector
- CAPR Health Care
- ARMN
- Exchange
- CAPR Nasdaq
- ARMN Nasdaq
- Market Cap
- CAPR 867.6M
- ARMN 697.3M
- IPO Year
- CAPR N/A
- ARMN N/A
- Fundamental
- Price
- CAPR $13.07
- ARMN $3.49
- Analyst Decision
- CAPR Strong Buy
- ARMN
- Analyst Count
- CAPR 7
- ARMN 0
- Target Price
- CAPR $39.29
- ARMN N/A
- AVG Volume (30 Days)
- CAPR 1.8M
- ARMN 440.1K
- Earning Date
- CAPR 11-13-2024
- ARMN 02-13-2025
- Dividend Yield
- CAPR N/A
- ARMN N/A
- EPS Growth
- CAPR N/A
- ARMN N/A
- EPS
- CAPR N/A
- ARMN N/A
- Revenue
- CAPR $23,228,045.00
- ARMN $484,511,000.00
- Revenue This Year
- CAPR N/A
- ARMN $46.47
- Revenue Next Year
- CAPR $74.85
- ARMN N/A
- P/E Ratio
- CAPR N/A
- ARMN N/A
- Revenue Growth
- CAPR 65.33
- ARMN 13.72
- 52 Week Low
- CAPR $3.52
- ARMN $2.60
- 52 Week High
- CAPR $23.40
- ARMN $5.16
- Technical
- Relative Strength Index (RSI)
- CAPR 37.42
- ARMN 37.74
- Support Level
- CAPR $12.25
- ARMN $3.30
- Resistance Level
- CAPR $20.75
- ARMN $4.14
- Average True Range (ATR)
- CAPR 1.62
- ARMN 0.17
- MACD
- CAPR -0.24
- ARMN -0.03
- Stochastic Oscillator
- CAPR 9.65
- ARMN 22.02
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.